Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $46.00 price objective on the stock. ZNTL has been the subject of several other reports. Wedbush raised their target price on Zentalis Pharmaceuticals from $12.00 […]
More Stories
SuRo Capital (NASDAQ:SSSS) & BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM) Head to Head Analysis
BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM – Get Free Report) and SuRo Capital (NASDAQ:SSSS – Get Free Report) are...
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) Announces January 16th IPO
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) expects to raise $12 million in an IPO on Thursday, January 16th, IPO Scoop...
Top humanitarian official issues ceasefire appeal during visit to Gaza City
The UN Humanitarian Coordinator for the Occupied Palestinian Territory called on Sunday for an end to the war in Gaza...
Comparing AGC (OTCMKTS:ASGLY) & Sonic Healthcare (OTCMKTS:SKHHY)
AGC (OTCMKTS:ASGLY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap industrial products companies,...
Comparing South Bow (SOBO) and Its Rivals
South Bow (NYSE:SOBO – Get Free Report) is one of 21 public companies in the “Pipelines, Except Natural Gas” industry,...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...